Yahoo India Web Search

Search results

1. www.prnewswire.com › news-releases › eirionEirion Therapeutics Announces Initiation of First-in-Human ...

   www.prnewswire.com › news-releases › eirion

   • Cached

   Jul 1, 2024 · Eirion Therapeutics, Inc. is a privately held, clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology. Eirion currently...

   • Eirion Therapeutics, Inc. Closes $40 Million Series A ...

     Eirion Therapeutics, Inc. is a privately held, clinical...

2. www.prnewswire.com › news-releases › eirionEirion Therapeutics, Inc. Closes $40 Million Series A ...

   www.prnewswire.com › news-releases › eirion

   • Cached

   Mar 9, 2021 · Eirion Therapeutics, Inc. is a privately held, clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology.

3. eirionthera.comEIRIONTHERA.COM

   eirionthera.com

   EIRIONTHERA.COM

4. www.healio.com › news › dermatologyEirion Therapeutics initiates phase 1 trial for ET-02 for ...

   www.healio.com › news › dermatology

   • Cached

   Jul 3, 2024 · ET-02 is a topical pharmaceutical that targets returning hair follicle stem cells to normal function when they have become defective or inactive in men facing age-related hair loss.

5. www.biospace.com › article › releasesEirion Therapeutics Announces Initiation of First-in-Human ...

   www.biospace.com › article › releases

   • Cached

   Oct 17, 2022 · Eirion Therapeutics Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial for the treatment of glabellar wrinkles using the next generation, ready-to-use liquid injectable neuromodulator AI-09.

6. www.prnewswire.com › news-releases › eirionEirion Therapeutics Announces Initiation of First-in-Human ...

   www.prnewswire.com › news-releases › eirion

   • Cached

   Oct 17, 2022 · Eirion Therapeutics, Inc. is a privately held, clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology.

7. People also ask

   Who is Eirion Therapeutics?

   • Eirion Therapeutics, Inc. is a privately held, clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology. Eirion currently has a rich pipeline of products focusing on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying.

   Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and

   www.prnewswire.com/news-releases/eirion-therapeutics-inc-closes-40-million-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology-ltd-301243384.html

   See all results for this question

   What is Eirion's clinical product et-01?

   • Eirion's Clinical Product Eirion's lead product ET-01 is a Phase 2 topical neuromodulator product candidate being developed for the treatment of lateral canthal lines (Crow's Feet wrinkles) and primary axillary hyperhidrosis (excessive underarm sweating).

   Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and

   www.prnewswire.com/news-releases/eirion-therapeutics-inc-closes-40-million-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology-ltd-301243384.html

   See all results for this question

   What does Eirion do?

   • Eirion currently has a rich pipeline of products focusing on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. In the future, Eirion plans to pursue additional indications that address other major unmet clinical needs for physicians and their patients.

   Eirion Therapeutics Announces Initiation of First-in-Human Clinical

   www.biospace.com/article/releases/eirion-therapeutics-announces-initiation-of-first-in-human-clinical-trial-evaluating-next-generation-ready-to-use-liquid-injectable-neuromodulator-ai-09-for-the-treatment-of-wrinkles/

   See all results for this question

   What licenses does Eirion offer?

   • One license is for Eirion's neuromodulator-based product candidates, ET-01 (topical) and AI-09 (injectable) for aesthetic indications; and a second license is for Eirion's small molecule product candidates, ET-02 (topical) and ET-03 (oral), which are intended for the treatment of hair loss and hair greying.

   Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and

   www.prnewswire.com/news-releases/eirion-therapeutics-inc-closes-40-million-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology-ltd-301243384.html

   See all results for this question

8. www.linkedin.com › company › eirion-therapeuticsEirion Therapeutics | LinkedIn

   www.linkedin.com › company › eirion-therapeutics

   Eirion Therapeutics | 69 followers on LinkedIn. Eirion is developing innovative prescription products for aesthetic medicine and medical dermatology.